In June 2025, the Swiss Nationanal Science Foundation (SNSF) announced that it would fund the EMPASTONE study. The study is being funded under the IICT programme (‘Investigator Initiated Clinical Trials’). Of a total of 47 applications, 6 (12%) were approved.
